Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide in Recurrent Childhood High-Grade Glioma
NCT00679354Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2008
- Primary completion
- Oct 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cilengitide in glioma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 16 weeks. Started Jun 2008; status: completed.
02
Drugs
cilengitide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00679354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00679354.